We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+15.65%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$515M
AUM Growth
+$28.6M
(+5.9%)
Cap. Flow
+$7.92M
Cap. Flow
% of AUM
1.54%
Top 10 Holdings %
Top 10 Hldgs %
33.78%
Holding
87
New
22
Increased
22
Reduced
21
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$18.1M |
| 2 |
Boston Scientific
BSX
|
+$14M |
| 3 |
Cardinal Health
CAH
|
+$12.7M |
| 4 |
Biogen
BIIB
|
+$10.6M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$15.5M |
| 2 |
Eli Lilly
LLY
|
+$15.2M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$14.2M |
| 4 |
Elevance Health
ELV
|
+$13.3M |
| 5 |
DexCom
DXCM
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Revvity
RVTY
$12.9B
| – | – |
-67,840
| Closed | -$9.65M |
|
77
Teladoc Health
TDOC
$1.21B
| – | – |
-124,369
| Closed | -$4.13M |
|
78
Xenon Pharmaceuticals
XENE
$6.29B
| – | – |
-97,281
| Closed | -$2.96M |
|
79
Zimmer Biomet
ZBH
$18.3B
| – | – |
-41,748
| Closed | -$4.39M |
|
80
Zai Lab
ZLAB
$2.86B
| – | – |
-156,554
| Closed | -$5.43M |
|
|
ITCI
81
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-78,277
| Closed | -$4.47M |
|
|
SWAV
82
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-46,966
| Closed | -$8.98M |
|
|
NSTG
83
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-188,500
| Closed | -$2.39M |
|
|
SGEN
84
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-31,311
| Closed | -$5.54M |
|
|
RETA
85
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-104,369
| Closed | -$3.17M |
|
|
ONEM
86
DELISTED
1Life Healthcare
ONEM
| – | – |
-730,582
| Closed | -$5.73M |
|
|
CCXI
87
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-574,029
| Closed | -$14.2M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q3 2022 Portfolio in Review
As of Q3 2022, Integral Health Asset Management held 87 positions worth $515M, up 5.9% from $486M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Integral Health Asset Management's Q3 2022 filing shows 22 new, 22 increased, 21 reduced and 22 closed positions. Its largest new stake was Baxter International: 300,000 shares worth $16.2M. The largest sale was AstraZeneca, an estimated $15.5M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.
- Integral Health Asset Management's largest Q3 2022 buy was Baxter International: 300,000 shares worth $16.2M.
- Integral Health Asset Management added most to CRISPR Therapeutics in Q3 2022, an estimated $10.1M increase.
- Integral Health Asset Management's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $15.2M.
- Integral Health Asset Management fully exited AstraZeneca in Q3 2022, selling an estimated $15.5M.
- Integral Health Asset Management's ten largest holdings make up 34% of its $515M portfolio in Q3 2022.
- Integral Health Asset Management opened 22 new positions and closed 22 in Q3 2022.
- Integral Health Asset Management's portfolio value rose 5.9% quarter-over-quarter to $515M.
Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.